According to the report, the Size of the North America Lyme Disease Diagnostic Market is valued at USD xx Million in 2021 and is poised to reach USD xx Million by 2026, growing at a CAGR of xx% during the forecast period 2021 to 2026.
Several prominent companies have expanded their Lyme disease diagnostics portfolios in response to the approval, offering novel Lyme disease diagnostics. T2 Biosystems created the T2Lyme Panel diagnostic technology for detecting germs that cause Lyme disease. As a result of these improvements, demand for enhanced Lyme disease diagnostics is expected to increase, propelling the North American Lyme disease diagnostics market ahead. If successful, developing a novel cytokine-based immunoassay for Lyme disease diagnostics could lead to earlier and more fast identification of the condition. A novel, rapid point-of-care Lyme diagnostic test based on lateral flow technology is being developed by researchers.
Metabolic biomarkers and biosignatures are being identified and characterized for improved diagnosis. All of this research is likely to contribute to new techniques of detecting Lyme disease and earlier diagnosis, accurate disease staging, and signs of successful therapy. The Lyme disease diagnostics market is expected to develop due to this. Early diagnosis and treatment of Lyme disease are critical for the most significant patient results. However, current diagnostic techniques are inconvenient, require a long time to analyze, and necessitate the expertise of laboratory specialists.
Due to the inaccuracy of these tests in diagnosing early cases of Lyme disease, there is an increasing demand for advanced clinical measures, which is driving the growth of the Lyme Disease Diagnostic Devices Market. Furthermore, rising rates of new vector-borne diseases, expanding government initiatives, and increasing healthcare expenditure drive the market forward.
In several emerging economies, a lack of information about different infections and Lyme disease diagnostics is projected to restrict market expansion to some extent. People are unaware of the disease, and its inefficiency hinders the growth of the Lyme disease diagnostics industry. In addition, there aren't enough investors to create diagnostic technologies for identifying Lyme disease, which restricts the market's potential growth.
This research report on the North America Lyme Disease Diagnostic Market has been segmented and sub-segmented into categories.
By Darkfield microscopy:
By Diagnostic Technologies:
By End User:
Geographically, North America dominated the Lyme disease diagnostics market in 2020, and this trend is expected to continue throughout the forecast period. The number of large diagnostics centers and significant market participants is highest in North America. During the forecast period, rising healthcare expenditures, early availability of innovative products, and a large patient base in the United States are likely to dominate regional shares in the Lyme disease diagnostics market.
Lyme disease diagnostics are in high demand due to an increase in the incidence and prevalence of the disease. Lyme disease is a common vector-borne disease in the United States and elsewhere, with over 400,000 new cases recorded yearly. Unfortunately, only a few tests on the market can reliably detect Lyme disease. Furthermore, the pathogenic bacteria's frequent mutations and genotypic variances boost the incidence among the population. Furthermore, the rising incidence of Lyme disease and the increasing need for diagnostic tests among the targeted patient pool support the Lyme disease diagnostic market.
KEY MARKET PLAYERS
Promising Companies leading the North America Lyme Disease Diagnostics Market Profiled in the Report are GlaxoSmithKline Pharmaceuticals Ltd, Alere Inc (ALR), Roche Diagnostics International Ltd, Affymetrix Inc, Siemens AG, Baxter International Inc, Fresenius Medical Care AG & Co, Bio-Rad Laboratories, Graphene Frontiers, Covance Inc, Boulder Diagnostics, Immunetics Inc.,
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Diagnostic Tests
5.1.2 Serological tests
184.108.40.206 ELISA (Enzyme-linked Immunosorbent Assay)
220.127.116.11 ELFA (Enzyme-linked Fluorescent Immunoassay)
18.104.22.168 Western Blot
5.1.3 Lymphocytic transformation test
5.1.4 Immunofluorescence staining
5.1.5 PCR Analysis
5.1.6 Urine antigen tests
5.1.7 Darkfield microscopy
5.1.8 Y-o-Y Growth Analysis, By Diagnostic Tests
5.1.9 Market Attractiveness Analysis, By Diagnostic Tests
5.1.10 Market Share Analysis, By Diagnostic Tests
5.2 Diagnostic Technologies
5.2.2 Molecular diagnostics
5.2.3 Brain MRI
5.2.4 Spinal tap
5.2.7 Monoclonal antibodies
5.2.8 Flow cytometry
5.2.9 Gel micro droplets
5.2.10 Y-o-Y Growth Analysis, By Diagnostic Technologies
5.2.11 Market Attractiveness Analysis, By Diagnostic Technologies
5.2.12 Market Share Analysis, By Diagnostic Technologies
5.3 End Users
5.3.2 Hospitals / Clinics
5.3.3 Pharmaceutical Industries
5.3.4 Pathology labs
5.3.5 Research Institutes
5.3.6 Y-o-Y Growth Analysis, By End Users
5.3.7 Market Attractiveness Analysis, By End Users
5.3.8 Market Share Analysis, By End Users
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Diagnostic Tests
188.8.131.52 By Diagnostic Technologies
184.108.40.206 By End Users
6.1.4 Market Attractiveness Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Diagnostic Tests
22.214.171.124 By Diagnostic Technologies
126.96.36.199 By End Users
6.1.5 Market Share Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Diagnostic Tests
220.127.116.11 By Diagnostic Technologies
18.104.22.168 By End Users
6.2 United States
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Siemens AG
8.3 GlaxoSmithKline Pharmaceuticals Ltd.
8.4 Fresenius Medical Care AG & Co.
8.5 Baxter International Inc.
8.6 Affymetrix Inc.
8.7 Immunetics Inc.
8.8 Boulder Diagnostics
8.9 Roche Diagnostics International Ltd.
8.10 Canon U.S. Life Sciences
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures